SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/197190"
 

Search: onr:"swepub:oai:gup.ub.gu.se/197190" > Improved outcome af...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Abrahamsson, Jonas,1954Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences (author)

Improved outcome after relapse in children with acute myeloid leukaemia.

  • Article/chapterEnglish2007

Publisher, publication year, extent ...

  • Wiley,2007

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/197190
  • https://gup.ub.gu.se/publication/197190URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-7067URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1945853URI
  • https://doi.org/10.1111/j.1365-2141.2006.06419.xDOI
  • https://lup.lub.lu.se/record/679528URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed. Data on disease characteristics and relapse treatment were related to outcome. Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%. Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival. Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality. Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1. In early relapse (<1 year in CR1), survival was 21 +/- 5% compared with 48 +/- 6% in late relapse. For children receiving re-induction therapy, survival in early relapse was 29 +/- 6% and 51 +/- 6% in late. Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. Survival was 62 +/- 6% in 64 children given SCT as part of their relapse therapy. A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Clausen, Niels (author)
  • Gustafsson, GöranKarolinska Institutet (author)
  • Hovi, Liisa (author)
  • Jonmundsson, Gudmundur (author)
  • Zeller, Bernward (author)
  • Forestier, ErikUmeå universitet,Pediatrik (author)
  • Heldrup, JesperLund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)pedi-jhe (author)
  • Hasle, Henrik (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper (creator_code:org_t)

Related titles

  • In:British journal of haematology: Wiley136:2, s. 229-2360007-10481365-2141

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view